Table 2.

Rate of response to chemotherapy after refractory disease

MDACC (n = 165)IA/MC (n = 82)LY.12 (CCTG) (n = 219)CORAL (LYSARC) (n = 170)Pooled* (N = 636)
Patients evaluated for response, n 165 82 106 170 523 
Response rate, % (95% CI) 20 26 26 31 26 (21-31) 
 CR rate 15 7 (3-15) 
 PR rate 13 18 25 16 18 (13-23) 
Response rate by refractory category, % (95% CI)      
 Primary refractory      
  RR — 25 27 10 20 (11-34) 
  CR rate — 10 3 (1-11) 
 Refractory to second-line or later-line therapy      
  RR 20 21 20 40 26 (17-39) 
  CR rate 20 18 10 (5-20) 
 Relapse ≤12 mo post-ASCT      
  RR 19 35 — 39 34 (24-45) 
  CR rate 10 — 25 15 (6-31) 
MDACC (n = 165)IA/MC (n = 82)LY.12 (CCTG) (n = 219)CORAL (LYSARC) (n = 170)Pooled* (N = 636)
Patients evaluated for response, n 165 82 106 170 523 
Response rate, % (95% CI) 20 26 26 31 26 (21-31) 
 CR rate 15 7 (3-15) 
 PR rate 13 18 25 16 18 (13-23) 
Response rate by refractory category, % (95% CI)      
 Primary refractory      
  RR — 25 27 10 20 (11-34) 
  CR rate — 10 3 (1-11) 
 Refractory to second-line or later-line therapy      
  RR 20 21 20 40 26 (17-39) 
  CR rate 20 18 10 (5-20) 
 Relapse ≤12 mo post-ASCT      
  RR 19 35 — 39 34 (24-45) 
  CR rate 10 — 25 15 (6-31) 

Response rate to the line of therapy was given after determination of refractory status.

CI, confidence interval; RR, response rate.

*

Higgin’s Q statistic, P = .18.

Data contain evidence that the patient proceeded to salvage therapy, but response information was not collected.

Close Modal

or Create an Account

Close Modal
Close Modal